Discounted Cash Flow (DCF) Analysis Levered
Centessa Pharmaceuticals plc (CNTA)
$3.9
0.00 (0.00%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|
| Revenue (%) | |||||||
| Operating Cash Flow | - | - | - | - | - | - | - |
| Operating Cash Flow (%) | |||||||
| Capital Expenditure | - | - | - | - | - | - | - |
| Capital Expenditure (%) | |||||||
| Free Cash Flow | - | - | - | - | - | - | - |
Weighted Average Cost Of Capital
| Share price | $ 3.9 |
|---|---|
| Beta | 0.000 |
| Diluted Shares Outstanding | 94.02 |
| Cost of Debt | |
| Tax Rate | -0.03 |
| After-tax Cost of Debt | 1.55% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 3.481 |
| Total Debt | 75.70 |
| Total Equity | 366.68 |
| Total Capital | 442.38 |
| Debt Weighting | 17.11 |
| Equity Weighting | 82.89 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | - | - | - | - | - | - | - |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - | - |
| Capital Expenditure | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| WACC | |||||||
| PV LFCF | - | - | - | - | - | - | - |
| SUM PV LFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 3.15 |
| Free cash flow (t + 1) | - |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | -519.38 |
| Equity Value | - |
| Shares Outstanding | 94.02 |
| Equity Value Per Share | - |